Anti-diabetic drug dispute leads to ICC award
The biopharmaceuticals arm of Merck has secured damages from a French spin-off company in an ICC arbitration over royalties owed under agreements to develop an anti-diabetic drug.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.